特拉維爾治療公司
US ˙ NasdaqGM ˙ US89422G1076

SecurityTVTX / Travere Therapeutics, Inc.
InstitutionQUANTITATIVE MASTER SERIES LLC - Master Small Cap Index Series
Latest Disclosed Ownership152,747 shares
Latest Disclosed Value $ 2,260,655
QUANTITATIVE MASTER SERIES LLC - Master Small Cap Index Series reports 6.72% increase in ownership of TVTX / Travere Therapeutics, Inc.

On August 26, 2025 - QUANTITATIVE MASTER SERIES LLC - Master Small Cap Index Series filed a NPORT-P form disclosing ownership of 152,747 shares of Travere Therapeutics, Inc. (US:TVTX) valued at $2,260,656 USD as of June 30, 2025. The entity filed a previous NPORT-P on May 28, 2025 disclosing 143,127 shares of Travere Therapeutics, Inc.. This represents a change in shares of 6.72% during the quarter. The current value of the position is $6,997,340 USD.

Institutional Ownership: 13F and NPORT Filings

The Security and Class in the table below are shown exactly as filed by the investor. We do our best to track continuity of investments through acquisitions, and this will be reflected in the table as changes in names. In addition to descriptive data, performance of the investment is shown over time. To calculate quarterly performance, we first calculate cost basis of the shares purchased during the quarter, then use that to calculate gross profit. Quarterly return is Gross Profit / Starting Portfolio value.

Note that cost basis is calculated and stored in thousands, so small quarterly changes in shares frequently result in a cost basis of zero.

Upgrade to unlock premium data and export to Excel .

Disclosed Equity Positions (from 13F/NPORT Filings)
File
Date
Effective
Date
Form Security Class ID Avg Price
Paid (Est)
Reported
Shares
ΔShares ΔShares
(%)
Reported
Value
(x1000)
ΔValue
(%)
Alloc
(%)
ΔAlloc ΔAlloc (%) Cost Basis
(x1000)
Unrealized
Gain/Loss
(x1000)
2025-08-26 2025-06-30 NP Travere Therapeutics EC US89422G1076 152,747 9,620 6.72 2,261 -11.86 0.0508
2025-05-28 2025-03-31 NP Travere Therapeutics EC US89422G1076 143,127 15,987 12.57 2,565 15.81 0.0615
2025-02-25 2024-12-31 NP Travere Therapeutics EC US89422G1076 127,140 -19,770 -13.46 2,215 7.74 0.0484
2024-11-26 2024-09-30 NP Travere Therapeutics EC US89422G1076 146,910 10,310 7.55 2,055 83.16 0.0389
2024-08-26 2024-06-30 NP Travere Therapeutics EC US89422G1076 136,600 6,454 4.96 1,123 11.86 0.0229
2024-05-28 2024-03-31 NP Travere Therapeutics EC US89422G1076 130,146 -5,773 -4.25 1,003 -17.85 0.0209
2024-02-26 2023-12-31 NP Travere Therapeutics EC US89422G1076 135,919 14,610 12.04 1,222 12.64 0.0261
2023-11-28 2023-09-30 NP Travere Therapeutics EC US89422G1076 121,309 -4,981 -3.94 1,085 -44.09 0.0283
2023-08-25 2023-06-30 NP Travere Therapeutics EC US89422G1076 126,290 27,704 28.10 1,940 -12.54 0.0460
2023-05-26 2023-03-31 NP Travere Therapeutics EC US89422G1076 98,586 2,502 2.60 2,217 9.75 0.0590
2023-02-24 2022-12-31 NP Travere Therapeutics EC US89422G1076 96,084 -748 -0.77 2,021 -15.30 0.0556
2022-11-25 2022-09-30 NP Travere Therapeutics EC US89422G1076 96,832 0 0.00 2,386 1.66 0.0684
2022-08-25 2022-06-30 NP Travere Therapeutics EC US89422G1076 96,832 4,980 5.42 2,346 -0.89 0.0648
2022-05-26 2022-03-31 NP Travere Therapeutics EC US89422G1076 91,852 1,768 1.96 2,367 -15.34 0.0551
2022-02-25 2021-12-31 NP Travere Therapeutics EC US89422G1076 90,084 0 0.00 2,796 28.02 0.0606
2021-11-24 2021-09-30 NP Travere Therapeutics EC US89422G1076 90,084 6,921 8.32 2,185 80.05 0.0481
2021-08-26 2021-06-30 NP Travere Therapeutics EC US89422G1076 83,163 0 0.00 1,213 -41.57 0.0260
2021-05-27 2021-03-31 NP Travere Therapeutics EC US89422G1076 83,163 3,854 4.86 2,077 -3.93 0.0471
2021-02-25 2020-12-31 NP Travere Therapeutics EC US89422G1076 79,309 0 0.00 2,162 47.61 0.0554
2020-11-25 2020-09-30 NP Retrophin EC US7612991064 79,309 8,838 12.54 1,464 1.81 0.0470
2020-08-27 2020-06-30 NP Retrophin EC US7612991064 70,471 2,046 2.99 1,438 44.09 0.0470
2020-06-01 2020-03-31 NP Retrophin EC US7612991064 68,425 4,931 7.77 998 10.77 0.0408
2020-02-27 2019-12-31 NP Retrophin EC 761299106 63,494 0 0.00 902 22.59 0.0271
2019-11-27 2019-09-30 NP Retrophin EC US7612991064 63,494 63,494 736 0.0243
Legend
Shares
The total number of shares held by the institution at the end of the reporting period (the effective date). This is provided in the filing.
Value
The total value of the shares as of the effective date. This is provided in the filing.
Avg. Share Price
The weighted average share price of the shares held by the institution. We use FIFO accounting to determine this price
Class
This is the security class as indicated by the filer. There are a variety of values for this field. Common values include "EC" = equity common, "EP" - equity preferred
Allocation (%)
The percent of the institution's portfolio that this position represents. This is provided in NPORT filings. For 13F filings, we calculate it.
Change in Allocation
The change in allocation from the prior reporting period. This is calculated as current allocation - prior allocation.
Change in Allocation (%)
The percent change in allocation from the prior reporting period. This is calculated as (current allocation - prior allocation) / prior allocation.
Cost Basis
The total cost of the shares held. This is calculated as reported shares * avg. share price
Unrealized Gain/Loss
This is the market value of the position as of the effective date minus the cost basis.